TCT 2017: New Analysis Finds Edwards' Sapien TAVR Saves $1,000s Per Patient
Executive Summary
Transcatheter aortic valve replacement with Edwards' Sapien XT or Sapien 3 is a highly cost-effective therapy for intermediate surgical risk patients with aortic stenosis compared with surgical aortic valve replacement, a new analysis of PARTNER 2A trial and the SAPIEN-3 Intermediate Risk registry.